Phadiatop (Allergy Screen)
Test Code: 200

Clinical and Procedure

Clinical Utility
The major use of the test is to help the primary care physician rule out allergy (IgE-mediated disease) as the cause of a patient's symptoms. Since inhalant allergy symptoms can be elusive and may resemble a bacterial or viral infection, a reliable atopy or allergy screen is often very cost effective. This test provides an accurate basis for the physician to decide on whether to refer the patient to an allergy specialist, institute general allergen avoidance procedures or to treat with one of the new non-sedating antihistamines.

Procedure
Enzyme Immunoassay. The ImmunoCAP Phadiatop test is a fluorescence substrate enzyme immunoassay system from Phadia. This test has been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.

Turnaround Time
1-2 business days from receipt of specimen

Specimen Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Order Code</th>
<th>CPT Code</th>
<th>NY Approved</th>
<th>Volume</th>
<th>Assay Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>serum</td>
<td>200</td>
<td>86005</td>
<td>Yes</td>
<td>1 mL serum (150 µL is the minimum volume)</td>
<td>Negative</td>
</tr>
</tbody>
</table>

Special Instructions
- Collect blood with a red top or SST and centrifuge to obtain serum. (150 µL is the minimum volume).
- 4 weeks ambient, 4 weeks refrigerated, >4 weeks freeze

Causes for Rejection
Lipemic samples may lead to rejection.

Disclaimer
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.

The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.

References

Matricardi PM et al. The sure of Phadiatop in massscreening programmes of inhalant allergies: advantages and limitations Clinical and Experimental Allergy 1990; 20: 151-155.

Williams PB, Siegel C, Portnoy J. Efficacy of a single diagnostic test for sensitization to common inhalant allergens. Annals of Allergy, Asthma & Immunology 2001; 86: in press.